Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation

Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantationSafety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation, Published online: 09 February 2018; doi:10.1038/s41409-018-0112-xSafety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation

Source: Bone Marrow Transplantation - February 9, 2018 Category: Hematology Authors: Alisha Pandit Houry Leblebjian Sarah P. Hammond Jacob P. Laubach Paul G. Richardson Lindsey R. Baden Francisco M. Marty Nicolas C. Issa Source Type: research